E-viri
Recenzirano
-
McKeegan, Evelyn M; Ansell, Peter J; Davis, Gerard; Chan, Sabrina; Chandran, Raj K; Gawel, Susan H; Dowell, Barry L; Bhathena, Anahita; Chakravartty, Arunava; McKee, Mark D; Ricker, Justin L; Carlson, Dawn M; Ramalingam, Suresh S; Devanarayan, Viswanath
Lung cancer (Amsterdam, Netherlands), 11/2015, Letnik: 90, Številka: 2Journal Article
Highlights • Linifanib is a potent and selective inhibitor of VEGF and PDGF receptors. • Linifanib has shown benefit in advanced NSCLC in first-line and relapsed settings. • We identified a biomarker profile predictive of improved survival with linifanib. • A signature combining CEA and CYFRA 21-1 predicted a favorable outcome. • This biomarker signature for linifanib therapy in NSCLC merits further evaluation.
